Similarly, MYS panel was designed to characterize the mutational landscape of MDS, MPN and AML, but it missed a number of relevant genes such as the transcription regulators GATA2, IKZF1, and PHF6 [25][26]. This evidence concerns the gene GATA2 and myeloproliferative neoplasm.